← Back to Clinical Trials
Recruiting Phase 4 NCT06653946

NCT06653946 the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06653946
Status Recruiting
Phase Phase 4
Sponsor Kafrelsheikh University
Condition Ischemic Stroke
Study Type INTERVENTIONAL
Enrollment 716 participants
Start Date 2022-07-01
Primary Completion 2024-07-01

Trial Parameters

Condition Ischemic Stroke
Sponsor Kafrelsheikh University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 716
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2022-07-01
Completion 2024-07-01
Interventions
AlteplaseAlteplase

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The investigators evaluated the impact of AF on different subtypes of post-alteplase hemorrhagic transformation of brain infarction.

Eligibility Criteria

Inclusion Criteria: * The investigators enrolled individuals of both genders, aged between 18 and 75, * All patients had acute first-ever embolic ischemic stroke and were eligible for thrombolysis. * All patients had Atrial fibrillation Exclusion Criteria: * The investigators excluded patients who had alteplase contraindications * The investigators excluded patients who did not receive the total dose of alteplase for any reason. * The investigators excluded patients who had a known history of persistent or recurrent CNS pathology (e.g., epilepsy, meningioma, multiple sclerosis) * The investigators excluded patients who had recurrent ischemic stroke diagnosed by appropriate clinical history and/or MRI brain findings. * The investigators excluded patients with symptoms of major organ failure, active malignancies, or an acute myocardial infarction within the previous six weeks. * The investigators also excluded pregnant and lactating patients with stroke due to venous thrombosis and strok

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology